Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
J&J's Rybrevant moves into first line in lung cancer subtype
While Takeda's Exkivity is out of the picture, ArriVent BioPharma and AstraZeneca spinout Dizal are each working on EGFR lung cancer meds.
Angus Liu
Mar 4, 2024 11:13am
Gilead secures $210M from Abingworth to fund Trodelvy trials
Feb 29, 2024 10:31am
AZ touts lung cancer advances for Tagrisso, ADC
Feb 20, 2024 1:09pm
JPM24: Merck expects $20B in new cancer sales from pipeline meds
Jan 9, 2024 6:20am
Amgen's request for full approval of Lumakras denied by FDA
Dec 27, 2023 8:00am
Lynparza fails to improve on Keytruda in first-line lung cancer
Dec 7, 2023 9:21am